SCHEMBL2984643

SCHEMBL2984643

CCC1(CCCCN2CCN(c3ccc(F)cc3)CC2)C(=O)Nc2ccc(F)cc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 20/20 1.00
HTR1A P08908 1/20 0.77
DRD2 P14416 1/20 0.77
DRD1 P21728 1/20 0.77
HTR2A P28223 1/20 0.77
HTR2C P28335 1/20 0.77
ADRA1A P35348 1/20 0.77
HTR6 P50406 1/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2975652 0.94 HTR7 (1.00) HTR7HTR1ADRD2DRD1HTR2A
SCHEMBL4015368 0.94 HTR7 (0.89) HTR7HTR1ADRD2DRD1HTR2A
SCHEMBL2984880 0.93 HTR7 (0.87) HTR7HTR1ADRD2DRD1HTR2A
SCHEMBL28765049 0.93 HTR7 (0.89) HTR7HTR1ADRD2DRD1HTR2A
Hydrochloric Acid SCHEMBL2978560 0.92 HTR7 (0.87) HTR7HTR1ADRD2DRD1HTR2A
SCHEMBL2980860 0.91 HTR7 (0.87) HTR7HTR1ADRD2DRD1HTR2A
SCHEMBL2981139 0.91 HTR7 (1.00) HTR7HTR1ADRD2DRD1HTR2A
SCHEMBL2988765 0.90 HTR7 (0.83) HTR7HTR1ADRD2DRD1HTR2A
SCHEMBL2977199 0.88 HTR7 (1.00) HTR7HTR1ADRD2DRD1HTR2A
Hydrochloric Acid SCHEMBL2987143 0.88 HTR7 (0.98) HTR7HTR1ADRD2DRD1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1993324-B 3-(((4-phenyl)-piperazin-1-yl)-alkyl)-3-alkyl-1,3-dihydro-2h-indol-2-one derivatives and related compounds for the treatment of central nervous system disorders EGYT GYOGYSZERVEGYESZETI GYAR 2010-12-15 CN disclosed
US-7786129-B2 Piperazine derivatives of dialkyl oxindoles EGIS GYOGYSZERGYAR NYRT (HU) 2010-08-31 US disclosed
EP-1776339-B1 3-(((4-PHENYL)-PIPERAZIN-1-YL)-ALKYL)-3-ALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS EGIS GYOGYSZERGYAR NYRT (HU) 2009-07-01 EP disclosed
US-20070232619-A1 Piperazine Derivatives of Dialkyl Oxindoles EGIS GYOGYSZERGYAR RT. (HU) 2007-10-04 US disclosed
CN-1993324-A 3-(((4-phenyl)-piperazin-1-yl)-alkyl)-3-alkyl-1,3-dihydro-2h-indol-2-one derivatives and related compounds for the treatment of central nervous system disorders EGIS GYOGYSZERGYAR NYRT (HU) 2007-07-04 CN disclosed
EP-1776339-A2 3-(((4-PHENYL)-PIPERAZIN-1-YL)-ALKYL)-3-ALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS EGIS Gyógyszergyár Nyrt (HU) 2007-04-25 EP disclosed
WO-2005109987-A9 3-(((4-PHENYL)-PIPERAZINE-1-YL)-ALKYL)-3-ALKYL-1, 3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS EGIS GYOGYSZERGYAR NYRT (HU) 2007-03-29 WO disclosed
WO-2005109987-A2 3-(((4-PHENYL)-PIPERAZINE-1-YL)-ALKYL)-3-ALKYL-1, 3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS EGIS GYÓGYSZERGYÁR NYRT. (HU) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232619-A1 Piperazine Derivatives of Dialkyl Oxindoles TPH2, DRD3, CNR2 HTR7 35/4885HTR1A 102/4885DRD2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.